Abstract
The discovery of VEGF-A's role in the pathogenesis of neovascular ocular disease provided a strong rationale for the development of anti-VEGF-based therapies. There is now ample evidence that anti-VEGF therapies are viable treatment options for these diseases. Nevertheless, large, randomized controlled trials are still awaited to confirm early safety and efficacy findings from small, open-label prospective studies.
Original language | English (US) |
---|---|
Pages (from-to) | 166-174 |
Number of pages | 9 |
Journal | Current opinion in ophthalmology |
Volume | 20 |
Issue number | 3 |
DOIs | |
State | Published - May 1 2009 |
Keywords
- Anti-vascular endothelial growth factor therapy
- Bevacizumab
- Neovascularization
- Pegaptanib sodium
- Ranibizumab
ASJC Scopus subject areas
- Ophthalmology